ITSN1 and androgen insensitivity syndrome: In conclusion, lnc‐ITSN1‐2 displays a good predictive value for AIS risk, and it is correlated with increased disease severity and inflammation, as well as worse RFS in AIS patients, which provides a potential biotarget for early prevention and monitoring disease progression to further improve prognosis in AIS patients.